EDWARD C. ALBINI - 15 May 2025 Form 4 Insider Report for SUTRO BIOPHARMA, INC. (STRO)

Role
CFO AND SECRETARY
Signature
/s/ David Pauling as attorney-in-fact for Edward C. Albini
Issuer symbol
STRO
Transactions as of
15 May 2025
Net transactions value
-$14,076
Form type
4
Filing time
19 May 2025, 16:11:42 UTC
Previous filing
07 Mar 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ALBINI EDWARD C CFO AND SECRETARY C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO /s/ David Pauling as attorney-in-fact for Edward C. Albini 19 May 2025 0001240014

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STRO Common Stock Options Exercise $0 +24,438 +19% $0.000000 156,519 15 May 2025 Direct
transaction STRO Common Stock Options Exercise $0 +11,156 +7.1% $0.000000 167,675 15 May 2025 Direct
transaction STRO Common Stock Options Exercise $0 +9,125 +5.4% $0.000000 176,800 15 May 2025 Direct
transaction STRO Common Stock Tax liability $14,076 -15,995 -9% $0.8800 160,805 15 May 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STRO Restricted Stock Unit (RSU) Options Exercise $0 -24,438 -47% $0.000000 27,312 15 May 2025 Common Stock 24,438 Direct F2, F3, F4
transaction STRO Restricted Stock Unit (RSU) Options Exercise $0 -11,156 -71% $0.000000 4,594 15 May 2025 Common Stock 11,156 Direct F2, F4, F5
transaction STRO Restricted Stock Unit (RSU) Options Exercise $0 -9,125 -100% $0.000000 0 15 May 2025 Common Stock 9,125 Direct F2, F4, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

EDWARD C. ALBINI is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2 Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F3 The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date.
F4 The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025.
F5 The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date.
F6 The RSUs vest as to 1/4th of the total award annually beginning on March 4, 2023, subject to continued service through each vesting date.